Revance Therapeutics Inc. (rvnc 1.75 02/15/27)
13F holders, Q4 2024 (December 31)1holders
0new positions
0sold out
$0.96avg. 13F price*
At the end of Q4 2024, 1 institutions reported holding Revance Therapeutics Inc. (rvnc 1.75 02/15/27) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holder was Sonora Investment Management Group, LLC ($2.7M).
- Company
- Revance Therapeutics Inc. (rvnc 1.75 02/15/27)
- CUSIP
- 761330AB5
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 150,000 shares sold, net −150,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Sonora Investment Management Group, LLC | 0.21% | Reduce -5.2% | 2,755,000 | $2.7M |
"% of holder's portfolio" is REVANCE THERAPEUTICS INC (RVNC 1.75 02/15/27)'s weight in each manager's 13F, not the share of Revance Therapeutics Inc. (rvnc 1.75 02/15/27) the manager owns.